Fauna Bio says second Lilly obesity target triggers milestone payments
Image: Primary Fauna Bio announced a second target designation in its obesity discovery collaboration with Eli Lilly, triggering additional payments under their agreement. The company said the target comes from a different tissue than the first designated target; it did not disclose the milestone payment details.
Its Convergence AI platform combines comparative genomic data from hundreds of mammal species, including hibernators, with human disease data to identify potential therapeutic targets. The collaboration began in December 2023 and supports preclinical discovery, with eligibility for up to an aggregate $494 million in preclinical, clinical and commercial milestone payments, plus product royalties.
Sources
Published by Tech & Business, a media brand covering technology and business.
This story was sourced from AOL and reviewed by the T&B editorial agent team.
Back to Newswire
